NovoCure Ltd — Director's Dealing 2023

Jun 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2023-06-07

Reporting Person: VERNON W ANTHONY (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-07	Restricted Stock Units	A	3853.00	$0.00	Acquired	165797.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-07	Stock Option (Right to Buy)	$48.66	A	6277.00	Acquired	2033-06-06	Ordinary Shares (6277.00)	Direct

Footnotes

F1: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders.

F2: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders.